Tyme Technologies (TYME) Shares up 12% Following Earnings, New Breast Cancer Trial Announcement

June 10, 2021 4:54 PM EDT
Get Alerts TYME Hot Sheet
Price: $1.38 +27.78%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Tyme Technologies (NASDAQ: TYME) shares are moving 12% higher following earnings and completion of strategic review.

The company announced a new OASIS Breast Cancer Trial for its drug candidate SM-88 in conjunction with Georgetown University.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Trader Talk

Related Entities

Earnings